Patient Oriented Research in Pediatric Kidney Disease

描述(由申请人提供)：苏珊·弗思，医学博士，博士，儿科学和流行病学教授，申请续签以患者为中心的研究生涯中期奖(K24)。弗思博士在指导和成就方面有着出色的记录。在该奖项的前4年，Furth博士成功地指导了医学生、研究员和初级教员；其中6人获得了NIH K23、KL2或K08职业发展奖，4人获得了基金会或试点补助金奖，他们都在学术界、政府或基金会从事研究。她继续参与和领导NIH/NIDDK的儿童慢性肾脏疾病队列研究(CKiD)，这是一项自2003年以来资助的针对美国和加拿大慢性肾脏病儿童的586人队列研究。对于此次续签申请，弗思博士将继续为博士后实习生和初级临床医生研究人员提供指导活动，其中大多数人还接受了宾夕法尼亚大学临床流行病学理学硕士项目的正式研究培训。弗思博士预计每年为2至3名博士后伙伴导师担任主要教师导师，并为在CKiD进行辅助研究的初级教师提供导师。她的以患者为中心的研究活动将继续解决慢性肾脏病的问题，重点放在个人依赖于透析或移植之前的疾病时期。CKiD已经达到了最初的注册目标，现在正在重新开放注册，并计划在2013年申请5年续签。在这次的K24更新中，Furth博士将通过CKiD和她在PediGFR研究中的角色为她的受训者扩大研究机会，PediGFR研究是CKiD的一个资助的辅助R01，它将包括CKiD研究以及欧洲逃逸和4C研究中1482名患有CKD的儿童的基因分型。CKiD和辅助的PediGFR研究提供了一个理想的平台，在其上进行CKD病因、进展和相关合并症的遗传贡献的研究。这项K24应用的其他研究目的是解决CKD中贫血和治疗耐药这一重大问题的遗传贡献。研究基因对贫血易感性和治疗耐药性的影响可能会产生创新的治疗靶点。横断面和纵向分析将扩大我们对慢性肾脏病贫血和治疗耐药的基因贡献的理解。将CKiD和PediGFR等现有资助研究的数据结合起来作为指导平台的方法将提高父母研究的生产率，并推动初级研究人员的职业生涯成为肾脏疾病研究的下一代领导者。

DESCRIPTION (provided by applicant): Susan Furth, M.D., Ph.D. is a Professor of Pediatrics and Epidemiology applying to renew a Mid-career Award in Patient Oriented Research (K24). Dr. Furth has an outstanding record of mentorship and accomplishment. During the first 4 years of this award, Dr. Furth successfully mentored medical students, fellows and junior faculty; 6 of whom have received NIH K23, KL2 or K08 career development awards, and 4 foundation or pilot grant awards, all are pursuing research in academia, government or foundations. She continues to work with and lead the NIH/NIDDK's Chronic Kidney Disease in Children Cohort (CKiD) Study, a 586-person cohort study of children with CKD in the US and Canada funded since 2003. For this renewal application, Dr. Furth will continue her mentoring activities for both post-doctoral trainees and junior clinician researchers, the majority also receive formal research training in the Masters of Science Program in Clinical Epidemiology at the University of Pennsylvania.. Dr. Furth anticipates being the primary faculty mentor for 2 to 3 post-doctoral fellow mentees per year, and providing mentorship for junior faculty pursuing ancillary studies in CKiD. Her patient oriented research activities will continue to address problems in CKD, focusing on the period of disease before individuals become dependent on dialysis or transplantation. CKiD has met its initial enrollment goals and is now re-opening enrollment, and planning for a 5 year renewal application in 2013. In this K24 renewal, Dr. Furth will extend the research opportunities for her mentees through CKiD and her role on the PediGFR study, a funded ancillary R01 to CKiD which will include genotyping of a cohort of 1482 children with CKD in the CKiD study, as well as in the European ESCAPE and 4C studies. CKiD, and the ancillary PediGFR study, provide an ideal platform on which to conduct the study of genetic contributions to CKD causes, progression and associated comorbidities. The additional research aims of this K24 application address the genetic contributions to the significant problem of anemia and treatment resistance in CKD. Investigating genetic contributions to anemia susceptibility and treatment resistance may yield innovative therapeutic targets. Cross- sectional and longitudinal analyses will expand our understanding of the genetic contributions to anemia and treatment resistance in CKD. The approach of combining data from existing funded studies including CKiD and PediGFR as a platform for mentorship will increase the productivity of the parent studies and propel the careers of junior investigators to become the next generation of leaders in kidney disease research.